Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Bonin, S; Donada, M; Bussolati, G; Nardon, E; Annaratone, L; Pichler, M; Chiaravalli, AM; Capella, C; Hoefler, G; Stanta, G.
A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Tumour Biol. 2016; 37(6):7295-7303
Doi: 10.1007/s13277-015-4543-3
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Höfler Gerald
- Pichler Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Genetic factors are known to affect the efficiency of therapy with monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) in patients with metastatic colorectal cancer (mCRC). At present, the only accepted molecular marker predictive of the response to anti-EGFR mAbs is the somatic mutation of KRAS and NRAS as a marker of resistance to anti-EGFR. However, only a fraction of KRAS wild-type patients benefit from that treatment. In this study, we show that the EGFR gene polymorphism rs1050171 defines, independently of RAS mutational status, a sub-population of 11 % of patients with a better clinical outcome after anti-EGFR treatment. Median PFS for patients with the GG genotype was 10.17 months compared to 5.37 of those with AG + AA genotypes. Taken together, our findings could be used to better define CRC populations responding to anti-EGFR therapy. Further studies in larger independent cohorts are necessary to validate the present observation that a synonymous polymorphism in EGFR gene impacts on clinical responsiveness.
- Find related publications in this database (using NLM MeSH Indexing)
- Adenocarcinoma - drug therapy
- Adenocarcinoma - genetics
- Adenocarcinoma - secondary
- Aged -
- Antibodies, Monoclonal - therapeutic use
- Antineoplastic Agents - therapeutic use
- Antineoplastic Combined Chemotherapy Protocols - administration & dosage
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Camptothecin - administration & dosage
- Camptothecin - analogs & derivatives
- Cetuximab - administration & dosage
- Cetuximab - therapeutic use
- Codon - genetics
- Colorectal Neoplasms - drug therapy
- Colorectal Neoplasms - genetics
- Disease-Free Survival -
- Drug Resistance, Neoplasm - genetics
- ErbB Receptors - antagonists & inhibitors
- Female -
- Fluorouracil - administration & dosage
- Genes, erbB-1 -
- Genes, ras -
- Humans -
- Irinotecan -
- Leucovorin - administration & dosage
- Male -
- Middle Aged -
- Neoplasm Proteins - antagonists & inhibitors
- Neoplasm Proteins - genetics
- Panitumumab -
- Polymorphism, Single Nucleotide -
- Protein Kinase Inhibitors - therapeutic use
- Proto-Oncogene Proteins p21(ras) - genetics
- Retrospective Studies -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- mCRC
- RAS mutation
- EGFR gene polymorphism rs1050171
- Synonymous SNP
- FFPE
- Survival